gatifloxacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibacterials, nalidixic acid derivatives 1280 112811-59-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • gatifloxacin anhydrous
  • gatifloxin
  • gatifloxacin
  • gatifloxacin hydrate
A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
  • Molecular weight: 375.40
  • Formula: C19H22FN3O4
  • CLOGP: -0.01
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 82.11
  • ALOGS: -2.77
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O
0.40 g P

ADMET properties:

PropertyValueReference
BA (Bioavailability) 96 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.80 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 10 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 60 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
March 28, 2003 FDA ALLERGAN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic reaction 135.98 30.99 51 1260 66049 63421662
Hypoglycaemia 104.28 30.99 41 1270 60024 63427687
Drug hypersensitivity 98.03 30.99 67 1244 310620 63177091
Drug intolerance 55.96 30.99 48 1263 308613 63179098
Toxic anterior segment syndrome 46.19 30.99 10 1301 1761 63485950
Corneal disorder 45.95 30.99 10 1301 1804 63485907
Visual acuity reduced 41.66 30.99 16 1295 21810 63465901
Cataract 40.82 30.99 21 1290 57032 63430679
Hyperglycaemia 40.70 30.99 19 1292 41848 63445863
Keratitis 34.73 30.99 9 1302 3413 63484298
Endophthalmitis 34.29 30.99 9 1302 3583 63484128

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 262.34 25.73 101 1769 54539 34900522
Hyperglycaemia 137.10 25.73 58 1812 39422 34915639
Intraocular pressure increased 82.59 25.73 24 1846 5359 34949702
Clostridium colitis 76.91 25.73 17 1853 1262 34953799
Visual acuity reduced 73.97 25.73 29 1841 16120 34938941
Blood glucose decreased 61.41 25.73 24 1846 13213 34941848
Corneal oedema 44.38 25.73 11 1859 1340 34953721
Blood glucose increased 39.78 25.73 31 1839 66687 34888374
Retinal haemorrhage 37.57 25.73 13 1857 5076 34949985
International normalised ratio increased 34.92 25.73 25 1845 47302 34907759
Corneal opacity 30.90 25.73 7 1863 579 34954482
Toxic anterior segment syndrome 30.89 25.73 8 1862 1161 34953900
Vitreous haemorrhage 29.50 25.73 9 1861 2364 34952697
Eye pain 28.31 25.73 14 1856 13448 34941613
Vision blurred 26.59 25.73 21 1849 45942 34909119

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 347.20 25.45 130 2600 101464 79640194
Hyperglycaemia 169.14 25.45 70 2660 70265 79671393
Intraocular pressure increased 107.16 25.45 30 2700 9175 79732483
Anaphylactic reaction 99.10 25.45 51 2679 83692 79657966
Visual acuity reduced 86.81 25.45 34 2696 29435 79712223
Corneal disorder 63.92 25.45 15 2715 2276 79739382
Corneal oedema 56.83 25.45 14 2716 2606 79739052
Toxic anterior segment syndrome 56.09 25.45 14 2716 2750 79738908
Blood glucose decreased 55.85 25.45 24 2706 26210 79715448
Clostridium colitis 55.71 25.45 14 2716 2825 79738833
Drug hypersensitivity 44.74 25.45 53 2677 298863 79442795
Drug intolerance 41.45 25.45 48 2682 264071 79477587
Corneal opacity 41.02 25.45 9 2721 1011 79740647
Endophthalmitis 40.28 25.45 13 2717 6415 79735243
Vision blurred 37.15 25.45 30 2700 105868 79635790
Blood glucose increased 34.99 25.45 30 2700 114945 79626713
Conjunctival hyperaemia 32.09 25.45 10 2720 4403 79737255
Keratitis fungal 31.78 25.45 6 2724 318 79741340
Corneal endotheliitis 31.65 25.45 5 2725 91 79741567
Cataract subcapsular 30.56 25.45 7 2723 954 79740704
International normalised ratio increased 29.70 25.45 24 2706 84697 79656961
Eye pain 28.21 25.45 17 2713 37561 79704097
Vitreous opacities 27.39 25.45 6 2724 669 79740989
Macular oedema 26.05 25.45 9 2721 5465 79736193

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01MA16 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
QUINOLONE ANTIBACTERIALS
Fluoroquinolones
ATC S01AE06 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Fluoroquinolones
FDA CS M0023650 Quinolones
CHEBI has role CHEBI:33281 antibiotics
CHEBI has role CHEBI:35441 antiinfective agents
CHEBI has role CHEBI:50750 inhibitors of type II topoisomerase
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D009883 Ophthalmic Solutions
MeSH PA D019999 Pharmaceutical Solutions
MeSH PA D059005 Topoisomerase II Inhibitors
MeSH PA D059003 Topoisomerase Inhibitors
FDA EPC N0000175937 Quinolone Antimicrobial

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute gonococcal cervicitis indication 20943002 DOID:10615
Staphylococcal pneumonia indication 22754005
Acute gonococcal urethritis indication 29864006
Pneumonia due to Streptococcus indication 34020007
Gonorrhea of rectum indication 42746002
Pneumonia due to Mycoplasma pneumoniae indication 46970008
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Haemophilus influenzae pneumonia indication 70036007
Acute bacterial sinusitis indication 75498004
Bacterial conjunctivitis indication 128350005 DOID:9700
Pneumococcal pneumonia indication 233607000
Chlamydial pneumonia indication 233609002
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Bacterial urinary infection indication 312124009
Infection due to Staphylococcus aureus indication 406602003
Acute exacerbation of chronic bronchitis indication 425748003
Urinary tract infection caused by Klebsiella indication 369001000119100
Moraxella Catarrhalis Chronic Bronchitis indication
E. Coli Pyelonephritis indication
Haemophilus Parainfluenzae Chronic Bronchitis indication
Legionella Pneumophila Pneumonia indication
Moraxella Catarrhalis Pneumonia indication
Staphylococcus Chronic Bronchitis indication
Complicated Proteus UTI indication
Streptococcus Pneumoniae Chronic Bronchitis indication
Skin and Skin Structure Streptococcus Infection indication
Haemophilus Influenzae Chronic Bronchitis indication
Haemophilus Parainfluenzae Pneumonia indication
Acute tuberculosis off-label use 25629007
Pulmonary tuberculosis off-label use 154283005 DOID:2957




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.23 acidic
pKa2 8.39 Basic
pKa3 1.22 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
DNA topoisomerase 4 Enzyme INHIBITOR CHEMBL CHEMBL
DNA gyrase Enzyme INHIBITOR CHEMBL CHEMBL
DNA topoisomerase 4 subunit A Enzyme IC50 5.92 CHEMBL
DNA gyrase subunit A Enzyme IC50 5.03 CHEMBL
DNA gyrase Enzyme IC50 6.30 CHEMBL

External reference:

IDSource
4021187 VUID
N0000148634 NUI
D00589 KEGG_DRUG
180200-66-2 SECONDARY_CAS_RN
4021187 VANDF
CHEBI:5280 CHEBI
GFN PDB_CHEM_ID
CHEMBL31 ChEMBL_ID
CHEMBL428581 ChEMBL_ID
CHEMBL251670 ChEMBL_ID
10816 IUPHAR_LIGAND_ID
DB01044 DRUGBANK_ID
L4618BD7KJ UNII
1546025 RXNORM
8587 MMSL
d04504 MMSL
007995 NDDF
116349004 SNOMEDCT_US
371238005 SNOMEDCT_US
C0753645 UMLSCUI
D000077734 MESH_DESCRIPTOR_UI
7423 INN_ID
5379 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ZYMAXID HUMAN PRESCRIPTION DRUG LABEL 1 0023-3615 SOLUTION/ DROPS 5 mg OPHTHALMIC NDA 25 sections
ZYMAXID HUMAN PRESCRIPTION DRUG LABEL 1 0023-3615 SOLUTION/ DROPS 5 mg OPHTHALMIC NDA 25 sections
ZYMAR HUMAN PRESCRIPTION DRUG LABEL 1 0023-9218 SOLUTION/ DROPS 3 mg OPHTHALMIC EXPORT ONLY 1 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 13668-526 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 20 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 13668-526 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 20 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 13668-526 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 20 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50383-189 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 23 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 50383-189 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 23 sections
ZYMAXID HUMAN PRESCRIPTION DRUG LABEL 1 54868-6303 SOLUTION/ DROPS 5 mg OPHTHALMIC NDA 25 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 57297-435 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 24 sections
gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 60758-615 SOLUTION/ DROPS 5 mg OPHTHALMIC NDA authorized generic 25 sections
gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 60758-615 SOLUTION/ DROPS 5 mg OPHTHALMIC NDA authorized generic 25 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 61314-672 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 23 sections
Gatifloxacin HUMAN PRESCRIPTION DRUG LABEL 1 68180-435 SOLUTION/ DROPS 5 mg OPHTHALMIC ANDA 24 sections